New Lyrica formulation performs in fibromyalgia, if not epilepsy; Congress at odds over FDA's role in compounding scandal;

@FiercePharma: New special report for a short week: The world's 20 best-selling generic drugs. Not just the usual suspects. Special Report | Follow @FiercePharma

> A controlled-release version of Pfizer's ($PFE) Lyrica fell short in a late-stage epilepsy trial, but proved helpful in fibromyalgia patients, according to top-line study results. Report

> FDA Commissioner Margaret Hamburg's appearance at a congressional hearing into the meningitis outbreak has triggered a debate over the agency's authority--or lack thereof--to police compounding pharmacies. Report

> Medicare's reimbursement policy on compounded drugs has been called into question in the wake of the meningitis outbreak linked to New England Compounding Center. Report

> The "party drug" Ecstasy, otherwise known as MDMA, has helped some U.S. veterans suffering from post-traumatic stress after fighting in Iraq and Afghanistan. Report

> Adding testosterone therapy to the erectile dysfunction drug Viagra doesn't improve performance any more than Viagra alone, a study found. Report

> India's Lupin launched a generic version of Abbott Laboratories' ($ABT) cholesterol pill TriCor. Report

Biotech News

 @FierceBiotech: GSK's new Promacta approval triggers a spike for Ligand shares. News | Follow @FierceBiotech

 @JohnCFierce: Celgene, Sanofi execs in (another) biopharma insider trading case. Is it that hard for insiders to get away with this? Story | Follow @JohnCFierce

 @RyanMFierce: Rare disease R&D and academic/pharma tie-up trends have melded in Shire's new alliance with Boston Children's. More | Follow @RyanMFierce

> Overnight success proves elusive for oral MS drugs. Item

> Review scolds FDA for lingering problems recruiting fresh talent. Story

Medical Device News

 @FierceMedDev: Spread the word - we're highlighting some of the top M&A targets in devices and diagnostics. Special Report | Follow @FierceMedDev

 @MarkHFierce: Could the device tax lead to supply problems? Item | Follow @MarkHFierce

 @DamianFierce: The SEC says employees of Stryker, Celgene and Sanofi carried on a complex insider trading scam. Report | Follow @DamianFierce

> Push to create pediatric medical devices brings Cincinnati Children's to Israel. Story

> Medtronic sees profit slip despite uptick in revenue. News

Biotech Research News

> Stem cells: A future treatment for Type 1 diabetes? News

> Northwestern U nanoparticle treats MS in mice. Article

> Radioactive injectable polymer safely kills tumors in mice. Story

> High risk of Alzheimer's disease linked to newly discovered gene mutation. Report

Pharma Manufacturing News

> Hikma temporarily closing West-Ward plant to fix new issues. Item

> Catalent cuts 45 at U.K. plant as demand 'changes'. Article

> Manufacturers return some drugs to market but shortages persist. News

> Feds probe if FedEx, UPS are delivery vehicles for illegal online pharmacies. Story

And Finally... Cue cute video: A paralyzed British daschund walks again after Cambridge University scientists use nose cells to bridge breaks in its spinal cord. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.